Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Pharming Group N.V. announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years.
As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of tasks and responsibilities, Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025.
In addition, shareholders also approved the proposal to approve certain components of the remuneration package of Mr. Chouraqui in his capacity as Executive Director and Chief Executive Officer.
A recording of the webcast, presentation slides from today’s EGM, and more details regarding both agenda items are available on the Pharming website in the Investor Relations section.